You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca and Merck & Co have announced that the European Medicines Agency has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). “There is no cure for NF1, a life-long and devastating condition, and current treatment choicAlready a subscriber Login You have…
The company has appointed Scott Coiante as Senior Vice President and Chief Financial Officer. An experienced finance executive in biotech, Mr. Coiante brings nearly 20 years of accounting, fundraising and operational experience to Aprea. “Aprea is leading the way in developing small moleculeAlready a subscriber Login You have read all…
The study describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for challenging drug targets. For this study, the teams leveragedAlready a subscriber Login You have read all your free articles, to…
The companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associatAlready a subscriber Login You have read all your…
